EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH PRIMARY SJOGREN'S SYNDROME: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED 24-WEEK STUDY

被引：1
|
作者：
Xu, D. [1 ]
Zhang, S. [1 ]
Huang, C. [2 ,3 ]
Huang, C. [2 ,3 ]
Qin, L. [4 ]
Li, X. [5 ]
Chen, M. [6 ]
Liu, X. [7 ]
Liu, Y. [8 ]
Li, Z. [9 ]
Hu, J. [10 ]
Bao, C. [11 ]
Wei, W. [12 ]
Tian, J. [13 ]
Duan, X. [14 ]
Van Vollenhoven, R. [15 ]
Fang, J. [16 ,17 ]
Zeng, X. [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Rheumatol, Beijing, Peoples R China
[2] Beijing Hosp, Rheumatol, Beijing, Peoples R China
[3] Guangzhou Med Univ, Affiliated Hosp 2, Rheumatol, Guangzhou, Peoples R China
[4] Huzhou Third Municipal Hosp, Rheumatol, Huzhou, Peoples R China
[5] Anhui Prov Hosp, Rheumatol, Hefei, Anhui, Peoples R China
[6] Xiamen Univ, Affiliated Hosp 1, Rheumatol, Xiamen, Peoples R China
[7] Shanxi Med Univ, Hosp 1, Rheumatol, Taiyuan, Shanxi, Peoples R China
[8] Sichuan Univ, West China Hosp, Rheumatol, Chengdu, Sichuan, Peoples R China
[9] Bengbu Med Coll, Affiliated Hosp 1, Rheumatol, Bengbu, Peoples R China
[10] Jiangxi Pingxiang Peoples Hosp, Rheumatol, Jianxi, Peoples R China
[11] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Rheumatol, Shanghai, Peoples R China
[12] Tianjin Med Univ, Gen Hosp, Rheumatol, Tianjin, Peoples R China
[13] Cent South Univ, Xiangya Hosp 2, Rheumatol, Xiangya, Peoples R China
[14] Nanchang Univ, Affiliated Hosp 2, Rheumatol, Nanchang, Jiangxi, Peoples R China
[15] Univ Amsterdam, Rheumatol, Med Ctr, Amsterdam, Netherlands
[16] Shanghai Tongi Univ, Rheumatol, Shanghai, Peoples R China
[17] RemeGen Co Ltd, Rheumatol, Yantai, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Clinical Trials; Randomized control trial; Sjogren syndrome;
D O I：
10.1136/annrheumdis-2023-eular.1728
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0142
引用
收藏
页码：94 / 95
页数：2
相关论文
共 50 条
  • [21] DESIGNING OFA PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN INHIBITOR, IN ADULTS WITH PRIMARY SJOGREN'S SYNDROME
    Hubbard, Jonathan J.
    Campbell, Kim
    Sivils, Kathy
    Hoffman, Robert W.
    Lo, Kim Hung
    Leu, Jocelyn H.
    Perdomo, Ana Maria Bravo
    Liva, Sophia G.
    Zuraw, Qing
    Stevens, Anne M.
    Ling, Leona E.
    Karcher, Keith
    Ramchandren, Sindhu
    Sun, Hong
    Scofield, R. Hal
    Seror, Raphaele
    Wallace, Daniel J.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2023, 29 : S55 - S56
  • [22] A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer's Disease
    Nakamura, Yu
    Imai, Yukimichi
    Shigeta, Masahiro
    Graf, Ana
    Shirahase, Toru
    Kim, Hyosung
    Fujii, Akifumi
    Mori, Joji
    Homma, Akira
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2011, 1 (01): : 163 - 179
  • [23] Iscalimab (CFZ533) in Patients with Sjogren's Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study
    Fisher, Benjamin A.
    Mariette, Xavier
    Papas, Athena S.
    Grader-Beck, Thomas
    Bootsma, Hendrika
    Ng, Wan-Fai
    Van Daele, Paul
    Finzel, Stephanie
    Elgueta, Sergio
    Hermann, Josef
    McCoy, Sara
    Bookman, Arthur
    Sopala, Monika
    Luo, Wen-Lin
    Scheurer, Cornelia
    Hueber, Wolfgang
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3242 - 3244
  • [24] Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial
    Kwak, Soo Heon
    Han, Kyung Ah
    Kim, Kyung-Soo
    Yu, Jae Myung
    Kim, EunSook
    Won, Jong Chul
    Kang, Jun Goo
    Chung, Choon Hee
    Oh, Seungjoon
    Choi, Sung Hee
    Won, Kyu Chang
    Kim, Sin Gon
    Cho, Seung Ah
    Cho, Bo Young
    Park, Kyong Soo
    DIABETES OBESITY & METABOLISM, 2023, 25 (07): : 1865 - 1873
  • [25] Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial
    Lukashevich, V.
    Schweizer, A.
    Shao, Q.
    Groop, P. -H.
    Kothny, W.
    DIABETES OBESITY & METABOLISM, 2011, 13 (10): : 947 - 954
  • [26] Efficacy and safety of canagliflozin rnonotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study
    Inagaki, Nobuya
    Kondo, Kazuoki
    Yoshinari, Toru
    Takahashi, Nahoko
    Susuta, Yutaka
    Kuki, Hideki
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (11) : 1501 - 1515
  • [27] A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
    King, Brett
    Guttman-Yassky, Emma
    Peeva, Elena
    Banerjee, Anindita
    Sinclair, Rodney
    Pavel, Ana B.
    Zhu, Linda
    Cox, Lori Ann
    Craiglow, Brittany
    Chen, Linda
    Banfield, Christopher
    Page, Karen
    Zhang, Weidong
    Vincent, Michael S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (02) : 379 - 387
  • [28] Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial
    Hong, S.
    Park, C. -Y.
    Han, K. A.
    Chung, C. H.
    Ku, B. J.
    Jang, H. C.
    Ahn, C. W.
    Lee, M. -K.
    Moon, M. K.
    Son, H. S.
    Lee, C. B.
    Cho, Y. -W.
    Park, S. -W.
    DIABETES OBESITY & METABOLISM, 2016, 18 (05): : 528 - 532
  • [29] Efficacy And Safety Of Once-Daily Umeclidinium/vilanterol 62.5/25 Mcg In COPD: A Randomized, Placebo-Controlled, 24-Week Study
    Donohue, J. F.
    Maleki-Yazdi, M.
    Kilbride, S.
    Mehta, R.
    Kalberg, C. J.
    Church, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [30] Efficacy and safety of abatacept in active primary Sjogren's syndrome: results of a phase III, randomised, placebo-controlled trial
    Baer, Alan N.
    Gottenberg, Jacques-Eric
    St Clair, E. William
    Sumida, Takayuki
    Takeuchi, Tsutomu
    Seror, Raphaele
    Foulks, Gary
    Nys, Marleen
    Mukherjee, Sumanta
    Wong, Robert
    Ray, Neelanjana
    Bootsma, Hendrika
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (03) : 339 - 348
12345